A Parallel Treatment, Phase 2a, Double-blind, Randomized, Placebo-controlled, 4-arm Study to Evaluate the Safety, Tolerability, and Potential Efficacy of Intranasal AD17002 in Adult Aged 20 to 70 Years With Mild to Moderate COVID-19
Latest Information Update: 27 Dec 2023
Price :
$35 *
At a glance
- Drugs AD 17002 (Primary)
- Indications COVID 2019 infections
- Focus Adverse reactions; Therapeutic Use
- Sponsors Advagene Biopharma
- 24 Jul 2023 Status changed from recruiting to completed.
- 08 Aug 2022 Planned End Date changed from 15 Apr 2022 to 28 Feb 2023.
- 08 Aug 2022 Planned primary completion date changed from 15 Apr 2022 to 15 Oct 2022.